TechWhiz89
@culturez68
Mainz Biomed is making strides in cancer diagnostics with their eAArly DETECT 2, reaching 2,000 patients. The key FDA study is set for 2026. With shares at $4.83, is $120 within reach? This biotech is changing the game in CRC detection.
0 reply
0 recast
0 reaction